93 related articles for article (PubMed ID: 38515744)
1. Disease swamps molecular signatures of genetic-environmental associations to abiotic factors in Tasmanian devil (Sarcophilus harrisii) populations.
Fraik AK; Margres MJ; Epstein B; Barbosa S; Jones M; Hendricks S; Schönfeld B; Stahlke AR; Veillet A; Hamede R; McCallum H; Lopez-Contreras E; Kallinen SJ; Hohenlohe PA; Kelley JL; Storfer A
Evolution; 2020 Jul; 74(7):1392-1408. PubMed ID: 32445281
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.
Flies AS; Lyons AB; Corcoran LM; Papenfuss AT; Murphy JM; Knowles GW; Woods GM; Hayball JD
Front Immunol; 2016; 7():581. PubMed ID: 28018348
[TBL] [Abstract][Full Text] [Related]
3. Lead exposure and source attribution for a mammalian scavenger before and after a culling program.
Jones EM; Koch AJ; Pay JM; Jones ME; Hamede RK; Hampton JO
Sci Total Environ; 2024 Aug; 940():173686. PubMed ID: 38830425
[TBL] [Abstract][Full Text] [Related]
4. Devil Facial Tumor Disease.
Pye RJ; Woods GM; Kreiss A
Vet Pathol; 2016 Jul; 53(4):726-36. PubMed ID: 26657222
[TBL] [Abstract][Full Text] [Related]
5. Complex associations between cancer progression and immune gene expression reveals early influence of transmissible cancer on Tasmanian devils.
Raven N; Klaassen M; Madsen T; Jones M; Hamilton DG; Ruiz-Aravena M; Thomas F; Hamede RK; Ujvari B
Front Immunol; 2024; 15():1286352. PubMed ID: 38515744
[TBL] [Abstract][Full Text] [Related]
6. Transmissible cancer influences immune gene expression in an endangered marsupial, the Tasmanian devil (Sarcophilus harrisii).
Raven N; Klaassen M; Madsen T; Thomas F; Hamede RK; Ujvari B
Mol Ecol; 2022 Apr; 31(8):2293-2311. PubMed ID: 35202488
[TBL] [Abstract][Full Text] [Related]
7. Lessons learnt from the Tasmanian devil facial tumour regarding immune function in cancer.
Peel E; Belov K
Mamm Genome; 2018 Dec; 29(11-12):731-738. PubMed ID: 30225648
[TBL] [Abstract][Full Text] [Related]
8. Intergenomic signatures of coevolution between Tasmanian devils and an infectious cancer.
Gallinson DG; Kozakiewicz CP; Rautsaw RM; Beer MA; Ruiz-Aravena M; Comte S; Hamilton DG; Kerlin DH; McCallum HI; Hamede R; Jones ME; Storfer A; McMinds R; Margres MJ
Proc Natl Acad Sci U S A; 2024 Mar; 121(12):e2307780121. PubMed ID: 38466855
[TBL] [Abstract][Full Text] [Related]
9. Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release.
Pye R; Patchett A; McLennan E; Thomson R; Carver S; Fox S; Pemberton D; Kreiss A; Baz Morelli A; Silva A; Pearse MJ; Corcoran LM; Belov K; Hogg CJ; Woods GM; Lyons AB
Front Immunol; 2018; 9():259. PubMed ID: 29515577
[TBL] [Abstract][Full Text] [Related]
10. Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils.
Pye R; Hamede R; Siddle HV; Caldwell A; Knowles GW; Swift K; Kreiss A; Jones ME; Lyons AB; Woods GM
Biol Lett; 2016 Oct; 12(10):. PubMed ID: 28120799
[TBL] [Abstract][Full Text] [Related]
11. Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies.
Zhou M; Tang Y; Xu W; Hao X; Li Y; Huang S; Xiang D; Wu J
Front Immunol; 2023; 14():1140463. PubMed ID: 37600773
[TBL] [Abstract][Full Text] [Related]
12. The evolution of two transmissible cancers in Tasmanian devils.
Stammnitz MR; Gori K; Kwon YM; Harry E; Martin FJ; Billis K; Cheng Y; Baez-Ortega A; Chow W; Comte S; Eggertsson H; Fox S; Hamede R; Jones M; Lazenby B; Peck S; Pye R; Quail MA; Swift K; Wang J; Wood J; Howe K; Stratton MR; Ning Z; Murchison EP
Science; 2023 Apr; 380(6642):283-293. PubMed ID: 37079675
[TBL] [Abstract][Full Text] [Related]
13. Transmissible cancer and longitudinal telomere dynamics in Tasmanian devils (Sarcophilus harrisii).
Madsen T; Klaassen M; Raven N; Dujon AM; Jennings G; Thomas F; Hamede R; Ujvari B
Mol Ecol; 2022 Dec; 31(24):6531-6540. PubMed ID: 36205590
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
